Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Sponsor
The Netherlands Cancer Institute
Study ID
NCT03448835
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    atezolizumab 1200 mg 5 cycles
  • Capecitabine — DRUG
    capecitabine 850 mg /m2 4 cycles
  • Oxaliplatin — DRUG
    oxaliplatin 100 mg/m2 4 cycles
  • Docetaxel — DRUG
    docetaxel 50 mg/m2 4 cycles

Study Details

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

Key Dates

Start date
Mar 7, 2018
Status verified
Jun 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: atezolizumab and chemotherapy
    1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel

Primary Outcome Measure

Incidence of adverse events following treatment (safety) [ Time Frame: until 100 days after last patient last study drug treatment ]

Related Studies